Commentary
Researchers associated with a prestigious teaching hospital released a sensationalistic and highly suspect study aimed at supporting Congressional legislation. The study, launched with an op-ed in the New York Times, points fingers at an evil, nebulous industry, yet forgets to note the researchers’ own role in exacerbating problems of drug affordability.
Another day in partisan America.
The tall tale told by Benjamin Rome, Alexander Egilman, and Aaron Kesselheim is that the average launch price for drugs rose 20 percent annually from $2,115 in 2008 to $180,007 in 2021.
You could cast suspicion on the study by noting that it was funded by key backers of Speaker Pelosi. And, not surprisingly, the experts argue that Congress must pass a drug price control bill sponsored by the Speaker….